

14. Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and Coronavirus Disease 2019: What we know so far. *Pathogens* 2020; 9:231.
15. Bosch BJ, van der Zee R, de Haan CA, et al. The Coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. *J Virol* 2003; 77:8801-8811.
16. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. *N Engl J Med* 2020; 382:1708-1720.
17. Grove J, Marsh M. The cell biology of receptor mediated virus entry. *J Cell Biol* 2011; 195:1071-1082.
18. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms. *Lancet Respir Med* 2020; 8:750-752.
19. Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* 2020; 182:429-446.
20. Madissoon E, Wilbrey Clark A, Miragaia RJ, et al. SCRNA-seq assessment of the human lung, spleen and esophagus tissue stability after cold preservation. *Genome Biol* 2019; 21:1.
21. Xu J, Xu X, Jiang L, et al. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. *Respir Res* 2020; 21:182.
22. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation and treatment of Coronavirus (COVID-19). *Stat Pearls* 2020.
23. Omura S. Ivermectin: 25 years and still going strong. *Int J Antimicrob Agents* 2008; 31:91-98.
24. Gupta D, Sahoo AK, Singh A. Ivermectin: Potential candidate for the treatment of COVID-19. *Braz J Infect Dis* 2020; 24:369-371.
25. Campbell WC, Benz GW. Ivermectin: A review of efficacy and safety. *J Vet Pharmacol Ther* 1984; 7:1-16.
26. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B* 2020; 10:766-788.
27. Juarez M, Schcolnik Cabrera A, Duenas Gonzalez A. The multitargeted drug ivermectin: From an anti-parasitic agent to a repositioned cancer drug. *Am J Cancer Res* 2018; 8:317-331.
28. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. *J Clin Pharmacol* 2002; 42:1122-1133.
29. Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. *J Antibiot* 2020; 73:593-602.
30. Scheim D. Ivermectin for COVID-19 treatment: Clinical response at quasi-threshold doses via hypothesized alleviation of CD147 mediated vascular occlusion. *SSRN J* 2020.
31. Gupta D, Sahoo AK, Singh A. Ivermectin: Potential candidate for the treatment of COVID-19. *Braz J Infect Dis* 2020; 24:369-371.
32. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: Trends, scope and relevance. *New Microbes New Infect* 2020; 35:100684.
33. Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of import in α/β mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J* 2012; 443:851-856.
34. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce venezuelan equine encephalitis virus replication. *Antiviral Res* 2013; 100:662-672.
35. Rizzo E. Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action. *Naunyn Schmiedebergs Arch Pharmacol* 2020; 393:1153-1156.
36. Sandler ZJ, Firpo MR, Omoba OS, et al. Novel ionophores active against La Crosse virus identified through rapid antiviral screening. *Antimicrob Agents Chemother* 2020; 64:e00086-20.
37. Dayer MR. Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatics study. *Preprints* 2020.
38. Dagher Janabi AH. Effective Anti-SARS-CoV-2 RNA dependent RNA polymerase drugs based on docking methods: The case of milbemycin, ivermectin and baloxavir marboxil. *Avicenna J Med Biotechnol* 2020; 12:246-250.
39. Caly L, Druce JD, Catton MG, et al. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020; 178:104787.
40. Rajter JC, Sherman MS, Fattah N, et al. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study. *Chest* 2021; 159:85-92.
41. EU Clinical Trials Register. Clinical trials for ivermectin and COVID-19. 2021.
42. Clinical Trials Registry India (CTRI). National Institute of Medical Statistics. 2020.
43. ClinicalTrials.gov. COVID-19 ivermectin. U.S. Department of Health and Human Services. 2020.
44. Taiub A, Chowdhury MM, Shahbaz M, et al. A randomized trial of ivermectin doxycycline and hydroxychloroquine azithromycin therapy on COVID-19 patients. *Research Square* 2020.

45. FDA. FDA letter to stakeholders: Do not use ivermectin intended for animals as treatment for COVID-19 in humans. 2020.